Treating a Chronic Autoimmune Inflammatory Disease: Targeting Pathophysiologic Cytokines in the Management of Rheumatoid Arthritis - A Whiteboard View

Treating a Chronic Autoimmune Inflammatory Disease: Targeting Pathophysiologic Cytokines in the Management of Rheumatoid Arthritis - A Whiteboard View is organized by Med Learning Group and will be held from Jul 26, 2018 - Jul 26, 2019.

Target Audience:
This activity is designed to meet the educational needs of rheumatologists, internists, nurse practitioners, physician assistants, and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.

Accreditation Statement:
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

Credit Designation Statement:
Med Learning Group designates this enduring activity for a maximum of 0.75 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Credit Information:
Purpose: This program would be beneficial for nurses involved in the care of patients with rheumatoid arthritis. Credits: 0.75 ANCC Contact Hours.

CNE Accreditation Statement: 
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Complete Conference Management will accredit this educational activity for 0.75 contact hour of continuing nursing education of RNs and APNs.

Program Overview:
This online activity is focused on the team involved in the management of patients with rheumatoid arthritis.

Learning Objectives:
After completing the CME activity, learners should be better able to:
• Review the role of IL-6 in both the intra-articular and extra-articular manifestations of rheumatoid arthritis
• Discuss the current medical society treatment recommendations for patients with moderate-to-severe rheumatoid arthritis
• Describe the utilization of interleukin-6 inhibitors as a treatment approach to reach a treat-to-goal target in patients with moderate-to-severe rheumatoid arthritis